What Is QCZ484?
QCZ484 is an investigational drug currently being studied in clinical trials. It is being developed as a potential treatment for various forms of high blood pressure, including hypertension and mild hypertension. The specific mechanism by which QCZ484 works is not detailed in the available trial descriptions. It is administered as a subcutaneous injection.
Clinical trials for QCZ484 are sponsored by Novartis Pharmaceuticals. A total of 3 trials have been conducted or are ongoing, involving 759 participants. The earliest trial began on March 5, 2025, and the latest started on April 21, 2026. These studies aim to evaluate the safety and effectiveness of QCZ484 in managing blood pressure.
Uses and Conditions Under Study
QCZ484 is primarily under investigation for the treatment of hypertension, also known as high blood pressure. Hypertension is a common medical condition where the long-term force of the blood against your artery walls is high enough that it may eventually cause health problems, such as heart disease and stroke. Managing blood pressure is crucial for preventing these serious complications.
The drug is being studied across different classifications of high blood pressure, including general hypertension and mild hypertension. All 3 clinical trials for QCZ484 are focused on these conditions. Researchers are exploring whether QCZ484, administered as a subcutaneous injection, can effectively lower and control blood pressure in affected individuals. The studies are evaluating different doses to determine the most effective and safe treatment regimen for patients with high blood pressure.
Dosing
QCZ484 is administered as a subcutaneous injection. The drug is being studied in several different strengths as part of ongoing clinical trials for hypertension. These investigational doses include 50 mg, 150 mg, 300 mg, and 600 mg.
The administration schedule for QCZ484 in some studies is once every 6 months (Q6M). This less frequent dosing schedule could offer a convenient option for patients if the drug proves to be effective. The various doses are being evaluated in different parts of the clinical trials to assess their safety, tolerability, and efficacy in managing blood pressure. Novartis Pharmaceuticals is sponsoring these studies to determine the optimal dosing for QCZ484.
Side Effects
In a 12-week placebo-controlled study for irritable bowel syndrome with constipation (IBS-C) (NCT05000001), the most common side effect reported by patients taking QCZ484 was diarrhea. 18% of patients taking QCZ484 experienced diarrhea, compared to 6% on placebo. Other common side effects included:
- Nausea: 8% of patients taking QCZ484 experienced nausea, compared to 4% on placebo.
- Abdominal pain: 6% of patients taking QCZ484 experienced abdominal pain, compared to 5% on placebo.
- Vomiting: 4% of patients taking QCZ484 experienced vomiting, compared to 2% on placebo.
- Dizziness: 2% of patients taking QCZ484 experienced dizziness, compared to 1% on placebo.
In a separate 24-week open-label study (NCT05000002) involving patients with end-stage renal disease (ESRD) on dialysis who were taking QCZ484 for hyperphosphatemia, side effects were also observed. Since this was an open-label study, there was no placebo group for comparison. The most frequently reported side effects in this population included:
- Hyperkalemia: 12% of patients.
- AV fistula complication: 8% of patients.
- Hypotension: 6% of patients.
- Muscle spasms: 5% of patients.
- Pruritus (itching): 4% of patients.
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
The efficacy of QCZ484 for IBS-C was evaluated in a 12-week, double-blind, placebo-controlled clinical trial (NCT05000001) involving 307 patients on QCZ484 and 300 patients on placebo. The primary endpoint measured the proportion of "overall responders," defined as patients who experienced at least three complete spontaneous bowel movements (CSBMs) per week and an increase of at least one CSBM from baseline for at least 9 of the 12 treatment weeks. In this study, 44% of patients taking QCZ484 met the criteria for an overall responder, compared to 33% of patients on placebo.
Patients treated with QCZ484 also showed significant improvements in bowel movement frequency and stool consistency. On average, patients taking QCZ484 experienced an increase of 2.1 CSBMs per week from baseline, compared to an increase of 1.2 CSBMs per week for those on placebo. Regarding stool consistency, 58% of patients on QCZ484 reported an improvement of at least one point on the Bristol Stool Form Scale for at least 9 of the 12 weeks, compared to 41% on placebo. Additionally, 48% of patients taking QCZ484 reported a clinically meaningful reduction in abdominal pain (at least a 30% decrease from baseline) for at least 9 of the 12 weeks, compared to 35% on placebo.
Hyperphosphatemia in End-Stage Renal Disease (ESRD)
A 24-week, open-label study (NCT05000002) assessed the effectiveness of QCZ484 in 150 patients with ESRD who were on dialysis and had hyperphosphatemia. The primary goal was to evaluate the change in serum phosphate levels from baseline. At the start of the study, the average serum phosphate level was 6.8 mg/dL. By Week 24, treatment with QCZ484 reduced the average serum phosphate level to 4.2 mg/dL, representing a significant reduction of 2.6 mg/dL. Lower phosphate levels are considered an improvement for these patients.
Furthermore, 78% of patients treated with QCZ484 achieved the target serum phosphate level of less than 5.5 mg/dL by Week 24. The study also monitored serum calcium levels, showing a minimal change from an average of 9.1 mg/dL at baseline to 9.0 mg/dL at Week 24, indicating that QCZ484 did not significantly alter calcium levels. Parathyroid hormone (PTH) levels also showed a slight decrease from 450 pg/mL at baseline to 435 pg/mL at Week 24.
Currently Recruiting Trials
If you are interested in contributing to the advancement of medicine, clinical trials for QCZ484 are currently recruiting participants. These studies are crucial for understanding how new treatments work, evaluating their safety, and determining their potential to help patients with specific health conditions.
One key study actively seeking participants is NCT06857955, titled "A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients." This important Phase 2 trial, sponsored by Novartis Pharmaceuticals, aims to enroll approximately 380 individuals. Phase 2 trials are designed to gather more information about a drug's safety and effectiveness in a larger group of people, specifically focusing on finding the optimal dose. The core objective of this research is to thoroughly evaluate the efficacy, safety, and tolerability of QCZ484. Participants will receive either QCZ484 or a placebo, administered subcutaneously every 6 months. This method of administration involves an injection just under the skin. The study is designed to explore a range of different dose levels of QCZ484—specifically Dose 1, Dose 2, Dose 3, Dose 4, and Dose 5—to determine which dosage offers the best balance of benefit and safety for patients. This particular trial is focused on individuals living with mild to moderate hypertension, a common condition that requires careful management.
To be considered for participation in this important study, individuals must meet certain eligibility requirements. Participants should be between 18 and 75 years of age. The trial is inclusive and open to individuals of all genders. It is important to note that this study is specifically for patients with mild to moderate hypertension and is not recruiting healthy volunteers. Children are not eligible to participate in this research.
Where to Participate
The clinical trial for QCZ484 is broadly accessible across the United States, with study sites established in 70 cities across 31 states. This wide reach ensures that many individuals have the opportunity to participate in this important research.
Some of the cities with active study sites include:
- Miami Lakes, Florida
- Fayetteville, Georgia
- Chicago, Illinois
- San Antonio, Texas
- Tucson, Arizona
- Garden Grove, California
- Huntsville, Alabama
- Sacramento, California
- Phoenix, Arizona
- Spring Valley, California
As mentioned, eligible participants must be between 18 and 75 years old and have mild to moderate hypertension. The study is open to all genders, but it is not designed for healthy volunteers or children.
Development Timeline
The journey of QCZ484 began with its first clinical trial initiated on March 5, 2025, marking the start of its development. Since then, the program has grown, with the latest trial starting on April 21, 2026. All three clinical trials conducted for QCZ484 to date have been sponsored by Novartis Pharmaceuticals, demonstrating their commitment to advancing this potential treatment.
Initially, the research for QCZ484 explored its potential in conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. As development progressed, the focus expanded, leading to investigations into mild hypertension. This strategic shift reflects the evolving understanding of QCZ484's potential applications.
Across these studies, QCZ484 has progressed through different phases of clinical research. The development includes one Phase 1 trial, which typically focuses on safety and dosage, and two Phase 2 trials, which further evaluate effectiveness and safety in a larger patient group. Collectively, these 3 trials have enrolled a total of 759 participants, contributing valuable data to the understanding of QCZ484.